Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15916220 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL605463 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL1162359 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL145000 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL2065907 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL147622 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| SCHEMBL3363663 | 1.00 | KDM4E (0.56) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| Bromide SCHEMBL9771320 | 0.98 | KDM4E (0.54) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| Hydrochloric Acid SCHEMBL9779186 | 0.98 | ALDH1A1 (0.57) | KDM4EADRA2AADRA2CLMNAHIF1A | |
| Benzoic Acid SCHEMBL6048463 | 0.87 | DAO (0.48) | KDM4EADRA2AADRA2CLMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456183-B2 | Guanidino compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1767525-A1 | Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7189727-B2 | Guanidino compounds | CHIRON CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1385823-B1 | GUANIDINO COMPOUNDS AS MELANOCORTIN-4 RECEPTOR (MC4-R) AGONISTS | CHIRON CORP (US) | 2006-12-13 | — | — | EP | disclosed |
| US-6960582-B2 | Guanidino compounds | CHIRON CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
| US-6951882-B2 | Substituted 4-phenyl-[1,3]-dioxanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-04 | — | — | US | disclosed |
| US-20050038027-A1 | Novel guanidino compounds | CHIRON CORPORATION | 2005-02-17 | — | — | US | disclosed |
| EP-1385823-A4 | NOVEL GUANIDINO COMPOUNDS | CHIRON CORP (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040248895-A1 | Novel guanidino compounds | CHU DANIEL (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040147593-A1 | Substituted 4-phenyl-[1,3]-dioxanes | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-07-29 | — | — | US | disclosed |
| WO-2004052876-A1 | SUBSTITUTED 4-PHENYL-[1,3]-DIOXANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-06-24 | — | — | WO | disclosed |
| US-6716840-B2 | AGONISTS OF THE MELANOCORTIN-4 RECEPTOR (?MC-4R?); USEFUL TREATING OBESITY AND TYPE 2 DIABETES | CHIRON CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040024211-A1 | Novel guanidino compounds | CHIRON CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1385823-A1 | NOVEL GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20020193595-A1 | Novel guanidino compounds | CHU DANIEL (US) | 2002-12-19 | — | — | US | disclosed |
| WO-2002081443-A1 | NOVEL GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2002-10-17 | — | — | WO | disclosed |
| US-5171753-A | Derivatives of 2-amino-1-phenylethanol having antiulcer activity | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038027-A1 | Novel guanidino compounds | MC4R, MC3R, GCKR | KDM4E 1005/4885ADRA2A 837/4885ADRA2C 318/4885 |
| US-20040024211-A1 | Novel guanidino compounds | MC4R, MC5R, MC3R | KDM4E 1318/4885ADRA2A 438/4885ADRA2C 202/4885 |
| US-20020193595-A1 | Novel guanidino compounds | MC4R, MC5R, MC3R | KDM4E 1005/4885ADRA2A 422/4885ADRA2C 175/4885 |
| US-20040147593-A1 | Substituted 4-phenyl-[1,3]-dioxanes | HCRTR2, HCRTR1, GPR119 | KDM4E 307/4885ADRA2A 291/4885ADRA2C 166/4885 |
| US-20040248895-A1 | Novel guanidino compounds | MC4R, MC5R, MC3R | KDM4E 1218/4885ADRA2A 315/4885ADRA2C 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.